Patent Application
20240026251
The present invention relates to antioxidants for use in treating solvents and in particular, to solvent compositions having a glycol ether solvent and at least one antioxidant. The present invention also relates to processes for inhibiting the generation of peroxide in glycol ether solvents.
Glycol ethers and glycol diethers (collectively referred to herein as “glycol ethers”) are among a class of solvents known to form peroxides on exposure to air. Glycol ether peroxides tend to decompose into aldehydes and carboxylic acids, which eventually results in the glycol ether solvents not meeting desired assay, acidity and color specifications. The formation of peroxides in glycol ethers can be curtailed by the addition of inhibitors, such as butylatedhydroxytoluene (BHT), which is known to be effective as an antioxidant at low parts per million levels. For this reason, BHT is widely used today with many known glycol ether solvents to provide the needed peroxide inhibition to the glycol ether solvents.
DOWANOL™ DPnB (dipropylene glycol n-butyl ether) is one of the known glycol ether solvents that is inhibited with BHT. DOWANOL™ DPnB containing BHT is a solvent that is used in a variety of cleaning products. And, DOWANOL™ DPnB with BHT is listed in the CleanGredients database of chemical ingredients that have been pre-approved by the US EPA to meet the Safer Choice Standard criteria. However, a recent decision by the EPA to remove compounds inhibited with BHT from the above list will cause the delisting of DOWANOL™ DPnB with BHT as well as other solvents that use BHT as an inhibitor, unless a BHT alternative can be implemented in the solvent. It would be desirable to have a BHT alternative antioxidant for such solvents.
It has been surprisingly found that antioxidants such as L-ascorbic acid-6-hexadecanoate, pentaerythritol tetrakis(3-(3,5-di-tert-butyl-4-hydroxyphenyl)propionate), at low concentrations (e.g., from 50 ppm to 1000 ppm by weight), can prevent peroxide and acid generation in glycol ethers. Therefore, the present invention is directed to the use of low concentrations of one or more of the above antioxidants in glycol ether solvents to provide a peroxide inhibited glycol ether solvent composition.
In one aspect, a solvent composition of the present invention comprises: (a) at least one glycol ether having the following formula:
R1—O—(CHR2CHR3)O)nR4;
wherein R1 is an alkyl group having 1 to 9 carbon atoms or a phenyl group; wherein R2 and R3 each individually is hydrogen, a methyl group or an ethyl group, provided that when R3 is a methyl group or an ethyl group, R2 is hydrogen and provided that when R2 is a methyl group or an ethyl group, R3 is hydrogen; wherein R4 is hydrogen or an alkyl group having 1 to 4 carbon atoms; and wherein n is an integer of 1 to 3; (b) at least one antioxidant, wherein the at least one antioxidant is selected from the group consisting of L-ascorbic acid-6-hexadecanoate, pentaerythritol tetrakis(3-(3,5-di-tert-butyl-4-hydroxyphenyl)propionate), and mixtures thereof, wherein the amount of the antioxidant in the solvent composition is less than or equal to 1,000 ppm by weight based on the total weight of the solvent composition; and (c) a peroxide, wherein the amount of the peroxide in the solvent composition is less than 20 ppm, based on the total weight of the solvent composition.
In another aspect, the present invention relates to a process for inhibiting the generation of peroxide in glycol ether solvents, the process comprising treating at least one glycol ether solvent with at least one antioxidant to reduce the content of a peroxide in the solvent to provide a glycol ether solvent composition, wherein the at least one glycol ether has the following formula:
R1—O—(CHR2CHR3)O)nR4;
wherein R1 is an alkyl group having 1 to 9 carbon atoms or a phenyl group; wherein R2 and R3 each individually is hydrogen, a methyl group or an ethyl group, provided that when R3 is a methyl group or an ethyl group, R2 is hydrogen and provided that when R2 is a methyl group or an ethyl group, R3 is hydrogen; wherein R4 is hydrogen or an alkyl group having 1 to 4 carbon atoms; and wherein n is an integer of 1 to 3; wherein the at least one antioxidant is selected from the group consisting of L-ascorbic acid-6-hexadecanoate, pentaerythritol tetrakis(3-(3,5-di-tert-butyl-4-hydroxyphenyl)propionate), and mixtures thereof; wherein the concentration of the antioxidant in the solvent composition is less than or equal to 1,000 ppm by weight, based on the total weight of the solvent composition; wherein the concentration of the peroxide in the solvent composition is less than 20 ppm, based on the total weight of the solvent composition.
In another embodiment, the present invention relates to a glycol ether solvent composition prepared using any of the inventive processes disclosed herein.
These and other embodiments are described in more detail in the Detailed Description.
As used throughout this specification, the abbreviations given below have the following meanings, unless the context clearly indicates otherwise: “<” means “less than”; “>” means “greater than”; “<” means “less than or equal to”; >” means “greater than or equal to”; “@” means “at”; m=micron(s), g=gram(s); mg=milligram(s); L=liter(s); mL=milliliter(s); g/mL=gram(s) per milliliter; ppm=parts per million; ppmw=parts per million by weight; rpm=revolutions per minute; m=meter(s); mm=millimeter(s); cm=centimeter(s); min=minute(s); s=second(s); hr=hour(s); ° C.=degree(s) Celsius; mmHg=millimeters of mercury; psig=pounds per square inch; kPa=kilopascal(s); %=percent, vol %=volume percent; and wt %=weight percent.
Some embodiments of the present invention relate to solvent compositions. In one embodiment, a solvent composition comprises: (a) at least one glycol ether having the following formula:
R1—O—(CHR2CHR3)O)nR4;
wherein R1 is an alkyl group having 1 to 9 carbon atoms or a phenyl group; wherein R2 and R3 each individually is hydrogen, a methyl group or an ethyl group, provided that when R3 is a methyl group or an ethyl group, R2 is hydrogen and provided that when R2 is a methyl group or an ethyl group, R3 is hydrogen; wherein R4 is hydrogen or an alkyl group having 1 to 4 carbon atoms; and wherein n is an integer of 1 to 3;
(b) at least one antioxidant, wherein the at least one antioxidant is selected from the group consisting of L-ascorbic acid-6-hexadecanoate, pentaerythritol tetrakis(3-(3,5-di-tert-butyl-4-hydroxyphenyl)propionate), and mixtures thereof, wherein the amount of the antioxidant in the solvent composition is less than or equal to 1,000 ppm by weight based on the total weight of the solvent composition; and
(c) a peroxide, wherein the amount of the peroxide in the solvent composition is less than 20 ppm, based on the total weight of the solvent composition.
In some embodiments, the glycol ether is selected from the group consisting of dipropylene glycol methyl ether; propylene glycol n-butyl ether; dipropylene glycol n-butyl ether; tripropylene glycol n-butyl ether; propylene glycol n-propyl ether; dipropylene glycol n-propyl ether; propylene glycol methyl ether acetate; dipropylene glycol methyl ether acetate; dipropylene glycol dimethyl ether; and mixtures thereof. In some embodiments, the amount of glycol ether in the solvent composition is 95 weight percent to 99.99 weight percent, based on the total weight of the solvent composition.
In some embodiments, the at least one antioxidant is L-ascorbic acid-6-hexadecanoate. The at least one antioxidant, in some embodiments, is pentaerythritol tetrakis(3-(3,5-di-tert-butyl-4-hydroxyphenyl)propionate). In some embodiments, the amount of antioxidant in the solvent composition is 50 ppm to 1,000 ppm, based on the total weight of the solvent composition.
In some embodiments, the concentration of peroxide present in the glycol ether solvent composition is less than 10 ppm, based on the total weight of the solvent composition.
The glycol ethers used in the present invention are usually highly pure compounds but can include mixtures of the homologous series. It is well known that when an alcohol is reacted with ethylene oxide or propylene oxide to produce a glycol ether, a mixture of products containing one, two or three ethylene oxide or propylene oxide units is obtained. This mixture is separated by distillation into the main components but sometimes a small quantity of one homolog can remain in a given product.
In some embodiments, the glycol ether(s) useful in the present invention is used at a purity of from 95% to 99.99% and can include one or more of the aforementioned homologue compounds. Typically, some commercial embodiments of glycol ether are mixtures of the homologues.
Examples of some commercially available glycol ethers useful in the present invention include, for example, products commercially available under the tradename DOWANOL™ from The Dow Chemical Company, such as propylene glycol n-butyl ether (DOWANOL™ PnB), dipropylene glycol n-butyl ether (DOWANOL™ DPnB), tripropylene glycol n-butyl ether (DOWANOL™ TPnB), propylene glycol n-propyl ether (DOWANOL™ PnP), dipropylene glycol n-propyl ether (DOWANOL™ DPnP), propylene glycol methyl ether acetate (DOWANOL™ PMA), dipropylene glycol methyl ether acetate (DOWANOL™ DPMA), and dipropylene glycol dimethyl ether (PROGLYDE™ DMM); and mixtures thereof.
The concentration of the glycol ether, component (a), in solvent compositions of the present invention can be, for example, 90 weight percent to 99.99 weight percent in some embodiments, or from 95 wt % to 99.99 wt % in some embodiments, based on the total weight of the solvent composition.
The antioxidant, component (b), used in embodiments of the present invention can include one or more compounds, including, for example, L-ascorbic acid-6-hexadecanoate, pentaerythritol tetrakis(3-(3,5-di-tert-butyl-4-hydroxyphenyl)propionate), and mixtures thereof.
One non-limiting examples of a commercially available antioxidant that can be used in embodiments of the present invention include Irganox 1010, which is pentaerythritol tetrakis(3-(3,5-di-tert-butyl-4-hydroxyphenyl)propionate) commercially available from BASF. L-ascorbic acid-6-hexadecanoate is CAS #137-66-6 and is commercially available from Spectrum Chemical Manufacturing Corporation or Sigma-Aldrich Co.
By including such antioxidants in the solvent compositions of the present invention, the one or more antioxidants can reduce both the concentration of peroxides present in the glycol ether and the acidity of the glycol ether.
The amount of the one or more antioxidants, component (b), that can be used in solvent compositions of the present invention can be, for example, 50 ppm to 1,000 ppm by weight in one embodiment, 50 ppm to 500 ppm by weight in other embodiments, 100 ppm to 400 ppm by weight in other embodiments, 150 ppm to 350 ppm by weight in other embodiments, and 200 ppm to 300 ppm by weight in other embodiments, based on the total weight of the solvent composition. If the concentration of the antioxidant is above 1,000 ppm, the antioxidant can generate color in the glycol ether; and if the concentration of the antioxidant is below 50 ppm in some embodiments, the antioxidant can fail to provide sufficient peroxide inhibition in the glycol ether.
The present invention also relates to processes for inhibiting the generation of peroxide in glycol ether solvents. In one embodiment, a process for inhibiting the generation of peroxide in glycol ether solvents comprises treating at least one glycol ether solvent with at least one antioxidant to reduce the content of a peroxide in the solvent to provide a glycol ether solvent composition, wherein the at least one glycol ether has the following formula:
R1—O—(CHR2CHR3)O)nR4;
wherein R1 is an alkyl group having 1 to 9 carbon atoms or a phenyl group; wherein R2 and R3 each individually is hydrogen, a methyl group or an ethyl group, provided that when R3 is a methyl group or an ethyl group, R2 is hydrogen and provided that when R2 is a methyl group or an ethyl group, R3 is hydrogen; wherein R4 is hydrogen or an alkyl group having 1 to 4 carbon atoms; and wherein n is an integer of 1 to 3; wherein the at least one antioxidant is selected from the group consisting of L-ascorbic acid-6-hexadecanoate, pentaerythritol tetrakis(3-(3,5-di-tert-butyl-4-hydroxyphenyl)propionate), and mixtures thereof; wherein the concentration of the antioxidant in the solvent composition is less than or equal to 1,000 ppm by weight, based on the total weight of the solvent composition; wherein the concentration of the peroxide in the solvent composition is less than 20 ppm, based on the total weight of the solvent composition. The at least one glycol ether can include any of the glycol ethers (component (a)) discussed above. The antioxidant, in some embodiments, can include one or more of L-ascorbic acid-6-hexadecanoate, pentaerythritol tetrakis(3-(3,5-di-tert-butyl-4-hydroxyphenyl)propionate), and mixtures thereof as discussed above.
The treating of the glycol ether with the antioxidant can be carried out in a number of ways including, for example, combining, blending or mixing (a) the at least one glycol ether and (b) the at least one antioxidant. The mixing of the components can be carried out by any well-known means and process equipment known in the art of compounding products together. The antioxidants used herein (L-ascorbic acid-6-hexadecanoate, pentaerythritol tetrakis(3-(3,5-di-tert-butyl-4-hydroxyphenyl)propionate)) are generally available as solids. With the antioxidants in solid form, they may be added to the glycol ether solvent in a mixing vessel from a preweighed bag. Alternatively, the antioxidants can be premixed with a small amount of the glycol ether solvent in a known concentration so as to make a concentrated antioxidant solution, and then a known amount of the concentrated antioxidant solution can be added to the bulk uninhibited glycol ether solvent from a shot tank, or using a pump, and mixed well to achieve the desired final concentration. The addition of the antioxidant to the glycol ether can be carried out at ambient temperature (about 25° C.) and ambient pressure (about 760 mmHg or 14.7 psig).
The amount of time used in the process to treat the glycol ether solvent with the antioxidant and fully inhibit the solvent can depend on a number of factors including the antioxidant used, the glycol ether to be treated, the technique used for treating, mixing speed, and other factors. The glycol ether is treated with antioxidant for at least 10 minutes in some embodiments, at least 25 minutes in some embodiments, at least 30 minutes in some embodiments, up to 60 minutes in some embodiments, from 10 to 50 minutes in some embodiments, from 10 to 30 minutes in some embodiments. In general, lower treatment times should be avoided so as to avoid improper dissolution of the antioxidant, but longer times would not cause issues.
The resulting inhibited glycol ether solvent composition after undergoing the inhibition treatment as described herein has a residual concentration of undesirable peroxide present in the glycol ether of <20 ppm by weight in some embodiments, from 0 ppm to 15 ppm by weight in other embodiments, and from 0.01 ppm to 10 ppm by weight in still another embodiment, each based on the total weight of the solvent composition. The residual concentration of peroxide present in the glycol ether is measured using the technique described in the Examples section herein. Glycol ethers have a peroxide specification since peroxides can interfere undesirably with some of the solvent applications.
In addition, the resulting glycol ether solvent composition after undergoing the treatment described above can have several beneficial properties including for example, control of peroxides, reduced acidity, and/or having an APHA color index of <25.
The inhibited glycol ether solvent compositions prepared as described herein can be advantageously useful in various applications including, for example, solvent-based and water-based formulations for cleaners, paints, personal care products, among many other products.
The following examples are presented to further illustrate the present invention in detail but are not to be construed as limiting the scope of the claims. Unless otherwise indicated, all parts and percentages are by weight.
Various terms and designations used in the Inventive Examples (Inv. Ex.) and the Comparative Examples (Comp. Ex.) are explained below. The various antioxidants compounds and solvents used in the Inv. Ex. and the Comp. Ex. are described as follows.
Two antioxidants are identified as being potentially compatible with glycol ether solvents and are selected for evaluation in a one-week accelerated stability test at 60° C. in the presence of air. The two antioxidants selected for the evaluation are: (1) L-ascorbic acid-6-hexadecanoate, and (2) pentaerythritol tetrakis(3-(3,5-di-tert-butyl-4-hydroxyphenyl)propionate) (commercially available from BASF as Irganox 1010).
A preliminary solubility determination is first conducted to determine if the antioxidants are sufficiently soluble in glycol ether solvents, and the antioxidants are found to be sufficiently soluble (e.g., up to at least 500 ppm-1,000 ppm concentration).
The above antioxidants are evaluated with the following three glycol ether solvents, available under the tradename DOWANOL™ from The Dow Chemical Company: (1) propylene glycol n-butyl ether (DOWANOL™ PnB, “PnB”), (2) dipropylene glycol n-butyl ether (DOWANOL™ DPnB, “DPnB”), and (3) dipropylene glycol n-propyl ether (DOWANOL™ DPnP, “DPnP”).
The antioxidants are evaluated for the antioxidants' ability to prevent or minimize peroxide formation and acid generation in the solvents. The performance of a solvent containing an antioxidant is compared against the performance of an uninhibited product.
General Procedure for Removing Peroxides from Solvents
Samples of uninhibited (i.e., no BHT) DOWANOL™ DPnP and DOWANOL™ DPnB are procured. These samples contain>50 ppm peroxides. Therefore, the peroxides had to be removed from the solvents before these solvents could be inhibited with the test antioxidants (inhibitors). The peroxides are effectively removed from the above listed uninhibited solvent samples by passing the solvents through a chromatographic column packed with: (i) about 20 mL of sand, (ii) 20 mL of Celite diatomaceous earth, and (iii) 300 mL of activated alumina. The above packed chromatographic column (packed in the order of (i)-(iii)) is capable of removing peroxides from the solvents to a concentration of 1 to 13 ppm from a solvent quantity of 2 liters. The solvents are subsequently distilled in the equipment described for PnB (next section) and promptly inhibited with the desired concentrations of the test inhibitors (antioxidants).
Removal of BHT from Solvents by Distillation
BHT had to be removed from the PnB before the solvent could be inhibited with the test antioxidants. This is accomplished by distilling the solvent away from the higher boiling BHT. The other two solvents, DPnB and DPnP, are also put through this procedure so as to eliminate potential other impurities from the passage through the alumina column. A 1-L four-necked round bottom flask equipped with a thermocouple well, a Teflon stir bar and two glass stoppers is clamped to the hood lattice and fitted with a 12-inch silver-jacketed vigreux column. A one-piece distillation head equipped with a thermocouple well, a cold finger condenser, and a fraction cutter with stopcock valves connected to a common nitrogen/vacuum line are placed on top of the column. A 500-mL round bottom flask is used as a receiver. A heating mantle connected to a digital temperature controller is attached to the 1-L flask and a magnetic stir plate is placed beneath the mantle. Control and high limit thermocouples leading from the digital temperature controller are placed between the mantle and the flask. Thermocouples leading from a digital temperature meter are placed inside the thermocouple wells in order to monitor the internal flask temperature and the distillate temperature. About 500 mL of the solvent is added to the flask through the open neck which is afterwards covered with a glass stopper. The stir plate is turned on at low speed. Dry ice is added to the vacuum trap and the vacuum pump turned on. The pressure in the apparatus could be adjusted to the desired value by means of a Tescom backpressure regulator and nitrogen flow from a 3 psig nitrogen line. The pressure is read by means of a digital Rosemount gauge. The system has a relief valve in place to safeguard against accidental over pressurization of the glass equipment. The pressure in the apparatus is reduced to about 10-20 mm Hg, and the flask is heated to get the solvent to distill. An initial 20 mL fraction of distillate is collected and discarded. The distillation is continued until a total of about 300 mL of distillate is collected. The removal of BHT is corroborated by GC analysis. The solvent is promptly inhibited with the desired concentrations of the test antioxidants as described below.
The desired amount of antioxidant is weighed to four decimal places into a 250-mL round bottom flask equipped with a built-in thermocouple well. A 70 mL aliquot of the test solvent is measured in a graduated cylinder and added to the tared flask. The weight of solvent is recorded. A Teflon stir bar is added, and the flask is attached to a reflux condenser open to the air and secured to the hood lattice. A heating mantle connected to a digital temperature controller is attached to the flask, and a stirring plate is placed beneath the mantle. Control and high temperature limit thermocouples leading from the temperature controller are placed between the flask and the mantle. A thermocouple leading from a separate digital temperature meter is placed inside the thermocouple well. The stirrer is started, and the temperature controller set to control the mantle temperature at about 80-90° C., which is the mantle temperature required to maintain the solvent in the flask at 60±1° C. This procedure is repeated with other identical experimental set ups that ran in parallel. After one week had elapsed, the heating is discontinued and the solvents allowed to cool to room temperature before measuring their peroxide and acid contents.
Sample acidity is measured as per the method described in ASTM D1613. The ASTM D1613 method requires a sample to be mixed with isopropanol and then titrated to the phenolphthalein end point of the sample with dilute sodium hydroxide. The general procedure used to measure the acid content of a solvent is as follows:
A 50-mL aliquot of anhydrous isopropanol is added into an oven-dried 250-mL Erlenmeyer flask containing a Teflon stir bar. Six drops of 0.5% alcoholic phenolphthalein are added to the flask using a disposable pipette. Then, the alcohol in the flask is titrated to a faint pink end point with 0.02 N NaOH solution. A 25-mL aliquot of a test sample of solvent is pipetted into the aforementioned flask, and the above-described titration repeated. The volume of NaOH solution used for the sample titration is recorded and used to calculate the acidity, as weight percent (wt %) acetic acid (AA), according to the following equation:
Wt% AA=(mL of NaOH solution)×(Normality of NaOH solution)×0.12/sample density(g/mL).
The solvent sample densities at 25° C. used in the above equation are as follows: PnB=0.875 g/mL; DPnB=0.907 g/mL; and DPnP=0.916 g/mL.
The peroxide content of test solvent samples is measured with an analytical method based on reaction of the peroxide with iodide ion followed by titration of liberated iodine with thiosulfate. This procedure is used to measure the peroxide content in glycol ether solvent compositions as described herein and as recited in the claims. The procedure used to measure the peroxide content of a solvent is as follows:
A 35.0 g sample of the test solvent is weighed into a 250-mL Erlenmeyer flask, followed by the addition of 100 mL of anhydrous isopropanol and 10 mL of glacial acetic acid. A blank is prepared by adding 100 mL of anhydrous isopropanol and 10 mL of glacial acetic acid into another 250-mL Erlenmeyer flask. A 1-mL aliquot of a saturated potassium iodide (KI) solution that had been previously prepared by mixing 201.9 g KI crystals with 168.3 g of deionized water, is pipetted into each flask, and a stopper is placed on each flask. The flasks are shaken lightly and then placed in a dark cabinet for 5 min. The flasks are then removed from the dark cabinet and a Teflon stir bar is added into the flasks. The contents of each flask are then titrated sequentially with 0.005 N sodium thiosulfate (prepared by dilution of a commercial 0.1 N sodium thiosulfate) until the solvent's yellow color disappeared as determined by visual observation. An observed solvent having a light yellow color is usually indicative of the solvent having a relatively low peroxide concentration which can be titrated with a low volume of the dilute sodium thiosulfate solution. An observed solvent having a dark yellow color is very likely indicative of the solvent having a high peroxide concentration. In this case, a non-diluted 0.1 N sodium thiosulfate is used as the titrant instead of the 0.005 N sodium thiosulfate. The peroxide concentration of the solvent is calculated as ppm peroxide according to the following equation:
Peroxide(ppm)=[(mL NaS2O3solution for sample being tested−mL NaS2O3solution for a blank sample)×N NaS2O3×8,000]/g sample
Summary of Results Table 1 shows the peroxide and acid concentrations in the glycol ether solvents with and without the antioxidants. In Table 1, “Antiox. 1” refers to L-ascorbic acid-6-hexadecanoate, and “Antiox. 2” refers to pentaerythritol tetrakis(3-(3,5-di-tert-butyl-4-hydroxyphenyl)propionate).
The results summarized in Table 1 show that both antioxidants effectively reduced peroxide and acid concentrations in all three glycol ethers to very low levels compared to the concentrations observed in uninhibited solvents (Comparative Examples A-C). The examples with DPnB (Inventive Examples 1-7) showed that the antioxidant concentration range of about 100 ppm to about 1000 ppm provided similar protection against peroxide and acid formation.
| Filing Document | Filing Date | Country | Kind |
|---|---|---|---|
| PCT/US2022/012219 | 1/13/2022 | WO |
| Number | Date | Country | |
|---|---|---|---|
| 63147872 | Feb 2021 | US |
